04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
21:36 , Nov 2, 2017 |  BioCentury  |  Finance

Frazier follows performance

Frazier Healthcare Partners plans to ramp up company creation with its new $419 million life sciences fund. According to Frazier’s Jamie Topper, Frazier Life Sciences IX, which closed on Oct. 31, will invest $5-$30 million...
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:56 , Aug 29, 2017 |  BC Extra  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
01:15 , May 6, 2015 |  BC Extra  |  Company News

Management tracks

Oncology company Cleveland BioLabs Inc. (NASDAQ:CBLI) named Langdon Miller president and CMO. Miller was VP of clinical research in oncology at Gilead Sciences Inc. (NASDAQ:GILD) after it acquired Calistoga Pharmaceuticals Inc. , where he had...
02:05 , Oct 11, 2014 |  BC Extra  |  Company News

Management tracks

Roth Capital Partners named John Chambers vice-chairman. Chambers, who joined ROTH in 2009, remains head of its healthcare investment banking group. He was previously the head of the healthcare and investment banking team at Merriman...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Zydelig idelalisib regulatory update

FDA approved an NDA from Gilead for Zydelig idelalisib for 3 blood cancers while EMA’s CHMP backed approval of the company’s MAA for the product for 2 blood cancers. FDA granted full approval to Zydelig...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

GS-9973: Additional Phase II data

Data from 41 evaluable chronic lymphocytic leukemia (CLL) patients who received twice-daily 800 mg oral GS-9973 for a median of 32 weeks in the single-arm, open-label, U.S. Phase II Study 102 showed that GS-9973 led...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

Idelalisib regulatory update

Gilead disclosed on a conference call to discuss its 4Q13 and 2013 financial results that FDA accepted and granted Priority Review to an NDA for idelalisib to treat chronic lymphocytic leukemia (CLL). The PDUFA date...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Idelalisib regulatory update

Gilead said FDA accepted for review an NDA for idelalisib to treat refractory indolent non-Hodgkin's lymphoma (NHL). The PDUFA date is Sept. 11. Gilead also said it submitted an NDA to FDA early last month...